Prelude Therapeutics Ratios (2019-2026) | PRLD

Ratios Dec2019 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
EBT Margin (Quarter)
-2,549.40%-859.08%-646.46%-320.60%-752.05%
EBIT Margin (Quarter)
-1,145.87%-845.78%-314.12%-307.59%-309.54%
EBITDA Margin (Quarter)
-1,145.87%-845.78%-314.12%-307.59%-309.54%
Operating Margin (Quarter)
-1,145.87%-845.78%-314.12%-307.59%-309.54%
Net Margin (Quarter)
-2,549.40%-859.08%-646.46%-320.60%-752.05%
FCF Margin (Quarter)
-911.97%-501.08%-294.08%409.91%-473.47%
Efficiency
Assets Average (Quarter)
359.71M340.40M318.16M292.88M269.86M250.69M231.41M209.41M239.47M269.56M268.09M262.39M235.70M210.76M186.37M158.39M128.09M104.84M118.03M130.48M
Asset Utilization Ratio (Quarter)
0.130.140.13
Leverage & Solvency
Interest Coverage Ratio (Quarter)
-0.21-0.22-0.44-2.68-3.83-2.51-0.30-3.20-6.00-12.84-77.55-0.79-0.87-0.82-63.59-1.51-1.45-0.95-23.63-0.70
Times Interest Earned (Quarter)
-0.21-0.22-0.44-2.68-3.83-2.51-0.30-3.20-6.00-12.84-77.55-0.79-0.87-0.82-63.59-1.51-1.45-0.95-23.63-0.70
Valuation
Enterprise Value (Quarter)
-343.12M-320.87M-295.28M-270.23M-250.35M-228.09M-205.77M-176.30M-259.03M-234.55M-236.98M-205.97M-183.89M-157.67M-137.66M-103.12M-124.76M-54.96M-103.21M-144.60M
Return Ratios
Return on Sales (Quarter)
-0.25%-0.09%-0.06%-0.03%-0.08%
Return on Capital Employed (Quarter)
-25.35%-31.23%-38.04%-44.09%-48.65%-53.75%-58.91%-64.49%-55.87%-50.77%-53.71%-56.18%-66.99%-75.99%-86.93%-100.99%-125.96%-139.70%-160.77%-94.79%
Return on Assets (Quarter)
-0.02%-0.02%-0.02%-0.02%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.02%-0.02%-0.02%-0.01%-0.01%